Tadalafil
Description
Name: Tadalafil
Type: small molecule
Groups: Array
Indication: Used for the treatment of erectile dysfunction.
Accession Number: DB00820 ( APRD00071)
Description: Tadalafil is an orally adminstered drug used to treat male erectile dysfunction (impotence). It is marketed worldwide under the brand name Cialis. It is a phosphodiesterase 5 (PDE5) inhibitor. Tadalafil's distinguishing pharmacologic feature is its longer half-life (17.5 hours) compared with Viagra and Levitra (4-5 hours). This longer half-life results in a longer duration of action and is, in part, responsible for the Cialis nickname of the "weekend pill." This longer half-life also is the basis of current investigation for tadalafil's use in pulmonary arterial hypertension as a once-daily therapy. [Wikipedia]
Structure:
Prescription Products:
Generic Prescription Products:
Over the Counter Products: Not Available
Prescription Products:
Generic Prescription Products:
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: Array
Indication: Used for the treatment of erectile dysfunction.
Accession Number: DB00820 ( APRD00071)
Description: Tadalafil is an orally adminstered drug used to treat male erectile dysfunction (impotence). It is marketed worldwide under the brand name Cialis. It is a phosphodiesterase 5 (PDE5) inhibitor. Tadalafil's distinguishing pharmacologic feature is its longer half-life (17.5 hours) compared with Viagra and Levitra (4-5 hours). This longer half-life results in a longer duration of action and is, in part, responsible for the Cialis nickname of the "weekend pill." This longer half-life also is the basis of current investigation for tadalafil's use in pulmonary arterial hypertension as a once-daily therapy. [Wikipedia]
Structure:
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Adcirca | tablet | 20 mg/1 | oral | 03-08-2009 | US | |
| Adcirca | tablet | 20 mg | oral | 19-01-2010 | Canada | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 5 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 10 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 2.5 mg/1 | oral | 07-01-2008 | US | |
| Cialis | tablet | 2.5 mg | oral | 18-01-2008 | Canada | |
| Cialis | tablet | 5.0 mg | oral | 18-01-2008 | Canada | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 11-12-2003 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet | 10 mg | oral | 11-12-2003 | Canada | |
| Cialis | tablet | 20 mg | oral | 25-11-2003 | Canada | |
| Cialis | tablet, film coated | 5 mg/1 | oral | 23-10-2008 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 2.5 mg/1 | oral | 07-01-2008 | US | |
| Cialis | tablet, film coated | 5 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 10 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 10 mg/1 | oral | 03-12-2003 | US | |
| Cialis | tablet, film coated | 5 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 10 mg/1 | oral | 26-11-2003 | US |
Generic Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Apo-tadalafil Pah | tablet | 20 mg | oral | 15-10-2015 | Canada |
Over the Counter Products: Not Available
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Adcirca | tablet | 20 mg/1 | oral | 03-08-2009 | US | |
| Adcirca | tablet | 20 mg | oral | 19-01-2010 | Canada | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 5 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 10 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 2.5 mg/1 | oral | 07-01-2008 | US | |
| Cialis | tablet | 2.5 mg | oral | 18-01-2008 | Canada | |
| Cialis | tablet | 5.0 mg | oral | 18-01-2008 | Canada | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 11-12-2003 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet | 10 mg | oral | 11-12-2003 | Canada | |
| Cialis | tablet | 20 mg | oral | 25-11-2003 | Canada | |
| Cialis | tablet, film coated | 5 mg/1 | oral | 23-10-2008 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 2.5 mg/1 | oral | 07-01-2008 | US | |
| Cialis | tablet, film coated | 5 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 10 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 20 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 10 mg/1 | oral | 03-12-2003 | US | |
| Cialis | tablet, film coated | 5 mg/1 | oral | 26-11-2003 | US | |
| Cialis | tablet, film coated | 10 mg/1 | oral | 26-11-2003 | US |
Generic Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Apo-tadalafil Pah | tablet | 20 mg | oral | 15-10-2015 | Canada |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|---|
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Adcirca | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Adcirca | Tadalafil |
| Apo-tadalafil Pah | Tadalafil |
| Brand Name | Ingredients |
|---|---|
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Adcirca | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Cialis | Tadalafil |
| Adcirca | Tadalafil |
| Apo-tadalafil Pah | Tadalafil |
Categories
- Vasodilator Agents
- Phosphodiesterase 5 Inhibitors
Pharmacology
Indication: Used for the treatment of erectile dysfunction.
Pharmacodynamics: Not Available
Mechanism of action: Tadalafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by tadalafil enhances erectile function by increasing the amount of cGMP.
Absorption: After single oral-dose administration, the maximum observed plasma concentration (Cmax) of tadalafil is achieved between 30 minutes and 6 hours (median time of 2 hours). Absolute bioavailability of tadalafil following oral dosing has not been determined.
Volume of distribution:
Protein binding: 94%
Metabolism: Not Available
Route of elimination: Tadalafil is excreted predominantly as metabolites, mainly in the feces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).
Half life: 17.5 hours
Clearance: Not Available
Toxicity: Oral, Rat LD50 = 2000 mg/kg, no deaths or toxicity.
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: Tadalafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by tadalafil enhances erectile function by increasing the amount of cGMP.
Absorption: After single oral-dose administration, the maximum observed plasma concentration (Cmax) of tadalafil is achieved between 30 minutes and 6 hours (median time of 2 hours). Absolute bioavailability of tadalafil following oral dosing has not been determined.
Volume of distribution:
- 63 L
Protein binding: 94%
Metabolism: Not Available
Route of elimination: Tadalafil is excreted predominantly as metabolites, mainly in the feces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).
Half life: 17.5 hours
Clearance: Not Available
Toxicity: Oral, Rat LD50 = 2000 mg/kg, no deaths or toxicity.
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Eli lilly co
- Eli lilly and co
- Eli Lilly and Company
Packagers:
- A-S Medication Solutions LLC
- Bryant Ranch Prepack
- Diversified Healthcare Services Inc.
- Eli Lilly & Co.
- Lake Erie Medical and Surgical Supply
- Lilly Del Caribe Inc.
- Nucare Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Rebel Distributors Corp.
- Redpharm Drug
- Southwood Pharmaceuticals
- United Therapeutics Corp.
Dosage forms
| Form | Route | Strength |
|---|---|---|
| Tablet | oral | 20 mg/1 |
| Tablet | oral | 10 mg |
| Tablet | oral | 2.5 mg |
| Tablet | oral | 20 mg |
| Tablet | oral | 5.0 mg |
| Tablet, film coated | oral | 10 mg/1 |
| Tablet, film coated | oral | 2.5 mg/1 |
| Tablet, film coated | oral | 20 mg/1 |
| Tablet, film coated | oral | 5 mg/1 |
| Form | Route | Strength |
|---|---|---|
| Tablet | oral | 20 mg/1 |
| Tablet | oral | 10 mg |
| Tablet | oral | 2.5 mg |
| Tablet | oral | 20 mg |
| Tablet | oral | 5.0 mg |
| Tablet, film coated | oral | 10 mg/1 |
| Tablet, film coated | oral | 2.5 mg/1 |
| Tablet, film coated | oral | 20 mg/1 |
| Tablet, film coated | oral | 5 mg/1 |
Prices
| Unit description | Cost | Unit |
|---|---|---|
| Cialis 2.5 mg tablet | $4.76 | tablet |
| Cialis 5 mg tablet | $4.76 | tablet |
| Cialis 10 mg tablet | $20.92 | tablet |
| Cialis 20 mg tablet | $20.92 | tablet |
| Cialis 30 5 mg tablet Box | $140.77 | box |
| Unit description | Cost | Unit |
|---|---|---|
| Cialis 2.5 mg tablet | $4.76 | tablet |
| Cialis 5 mg tablet | $4.76 | tablet |
| Cialis 10 mg tablet | $20.92 | tablet |
| Cialis 20 mg tablet | $20.92 | tablet |
| Cialis 30 5 mg tablet Box | $140.77 | box |
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|---|---|---|
| 2181377 | Canada | 2002-05-28 | 2015-01-19 |
| 2379948 | Canada | 2008-03-25 | 2020-04-26 |
| 6140329 | United States | 1996-07-11 | 2016-07-11 |
| 6821975 | United States | 2000-11-19 | 2020-11-19 |
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|---|
| Acebutolol | Tadalafil may increase the antihypertensive activities of Acebutolol. |
| Alfuzosin | Tadalafil may increase the hypotensive activities of Alfuzosin. |
| Aliskiren | Tadalafil may increase the antihypertensive activities of Aliskiren. |
| Alprostadil | The risk or severity of adverse effects can be increased when Tadalafil is combined with Alprostadil. |
| Amiloride | Tadalafil may increase the antihypertensive activities of Amiloride. |
| Amlodipine | Tadalafil may increase the antihypertensive activities of Amlodipine. |
| Amyl Nitrite | Tadalafil may increase the vasodilatory activities of Amyl Nitrite. |
| Aprepitant | The serum concentration of Tadalafil can be increased when it is combined with Aprepitant. |
| Atazanavir | The serum concentration of Tadalafil can be increased when it is combined with Atazanavir. |
| Atenolol | Tadalafil may increase the antihypertensive activities of Atenolol. |
| Avanafil | The risk or severity of adverse effects can be increased when Tadalafil is combined with Avanafil. |
| Azilsartan medoxomil | Tadalafil may increase the antihypertensive activities of Azilsartan medoxomil. |
| Benazepril | Tadalafil may increase the antihypertensive activities of Benazepril. |
| Bendroflumethiazide | Tadalafil may increase the antihypertensive activities of Bendroflumethiazide. |
| Betaxolol | Tadalafil may increase the antihypertensive activities of Betaxolol. |
| Bisoprolol | Tadalafil may increase the antihypertensive activities of Bisoprolol. |
| Boceprevir | The serum concentration of Tadalafil can be increased when it is combined with Boceprevir. |
| Bosentan | The serum concentration of Tadalafil can be decreased when it is combined with Bosentan. |
| Bumetanide | Tadalafil may increase the antihypertensive activities of Bumetanide. |
| Candesartan | Tadalafil may increase the antihypertensive activities of Candesartan. |
| Captopril | Tadalafil may increase the antihypertensive activities of Captopril. |
| Carbamazepine | The serum concentration of Tadalafil can be decreased when it is combined with Carbamazepine. |
| Carvedilol | Tadalafil may increase the antihypertensive activities of Carvedilol. |
| Ceritinib | The serum concentration of Tadalafil can be increased when it is combined with Ceritinib. |
| Chlorothiazide | Tadalafil may increase the antihypertensive activities of Chlorothiazide. |
| Chlorthalidone | Tadalafil may increase the antihypertensive activities of Chlorthalidone. |
| Cilazapril | Tadalafil may increase the antihypertensive activities of Cilazapril. |
| Clarithromycin | The serum concentration of Tadalafil can be increased when it is combined with Clarithromycin. |
| Clevidipine | Tadalafil may increase the antihypertensive activities of Clevidipine. |
| Clonidine | Tadalafil may increase the antihypertensive activities of Clonidine. |
| Cobicistat | The serum concentration of Tadalafil can be increased when it is combined with Cobicistat. |
| Conivaptan | The serum concentration of Tadalafil can be increased when it is combined with Conivaptan. |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Tadalafil. |
| Darunavir | The serum concentration of Tadalafil can be increased when it is combined with Darunavir. |
| Dasatinib | The serum concentration of Tadalafil can be increased when it is combined with Dasatinib. |
| Diltiazem | Tadalafil may increase the antihypertensive activities of Diltiazem. |
| Doxazosin | Tadalafil may increase the hypotensive activities of Doxazosin. |
| Enalapril | Tadalafil may increase the antihypertensive activities of Enalapril. |
| Enalaprilat | Tadalafil may increase the antihypertensive activities of Enalaprilat. |
| Enzalutamide | The serum concentration of Tadalafil can be decreased when it is combined with Enzalutamide. |
| Eplerenone | Tadalafil may increase the antihypertensive activities of Eplerenone. |
| Eprosartan | Tadalafil may increase the antihypertensive activities of Eprosartan. |
| Erythrityl Tetranitrate | Tadalafil may increase the vasodilatory activities of Erythrityl Tetranitrate. |
| Esmolol | Tadalafil may increase the antihypertensive activities of Esmolol. |
| Ethacrynic acid | Tadalafil may increase the antihypertensive activities of Ethacrynic acid. |
| Ethanol | Ethanol may increase the hypotensive activities of Tadalafil. |
| Etravirine | The serum concentration of Tadalafil can be decreased when it is combined with Etravirine. |
| Felodipine | Tadalafil may increase the antihypertensive activities of Felodipine. |
| Fluconazole | The serum concentration of Tadalafil can be increased when it is combined with Fluconazole. |
| Fosaprepitant | The serum concentration of Tadalafil can be increased when it is combined with Fosaprepitant. |
| Fosinopril | Tadalafil may increase the antihypertensive activities of Fosinopril. |
| Fosphenytoin | The serum concentration of Tadalafil can be decreased when it is combined with Fosphenytoin. |
| Furosemide | Tadalafil may increase the antihypertensive activities of Furosemide. |
| Fusidic Acid | The serum concentration of Tadalafil can be increased when it is combined with Fusidic Acid. |
| Guanfacine | Tadalafil may increase the antihypertensive activities of Guanfacine. |
| Hydralazine | Tadalafil may increase the antihypertensive activities of Hydralazine. |
| Hydrochlorothiazide | Tadalafil may increase the antihypertensive activities of Hydrochlorothiazide. |
| Idelalisib | The serum concentration of Tadalafil can be increased when it is combined with Idelalisib. |
| Indapamide | Tadalafil may increase the antihypertensive activities of Indapamide. |
| Indinavir | The serum concentration of Tadalafil can be increased when it is combined with Indinavir. |
| Irbesartan | Tadalafil may increase the antihypertensive activities of Irbesartan. |
| Isosorbide | Tadalafil may increase the vasodilatory activities of Isosorbide. |
| Isosorbide Dinitrate | Tadalafil may increase the vasodilatory activities of Isosorbide Dinitrate. |
| Isosorbide Mononitrate | Tadalafil may increase the vasodilatory activities of Isosorbide Mononitrate. |
| Isradipine | Tadalafil may increase the antihypertensive activities of Isradipine. |
| Itraconazole | The serum concentration of Tadalafil can be increased when it is combined with Itraconazole. |
| Ivacaftor | The serum concentration of Tadalafil can be increased when it is combined with Ivacaftor. |
| Ketoconazole | The serum concentration of Tadalafil can be increased when it is combined with Ketoconazole. |
| Labetalol | Tadalafil may increase the antihypertensive activities of Labetalol. |
| Lisinopril | Tadalafil may increase the antihypertensive activities of Lisinopril. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Tadalafil. |
| Losartan | Tadalafil may increase the antihypertensive activities of Losartan. |
| Luliconazole | The serum concentration of Tadalafil can be increased when it is combined with Luliconazole. |
| Mannitol | Tadalafil may increase the antihypertensive activities of Mannitol. |
| Mecamylamine | Tadalafil may increase the antihypertensive activities of Mecamylamine. |
| Methyclothiazide | Tadalafil may increase the antihypertensive activities of Methyclothiazide. |
| Methyldopa | Tadalafil may increase the antihypertensive activities of Methyldopa. |
| Metolazone | Tadalafil may increase the antihypertensive activities of Metolazone. |
| Metoprolol | Tadalafil may increase the antihypertensive activities of Metoprolol. |
| Mifepristone | The serum concentration of Tadalafil can be increased when it is combined with Mifepristone. |
| Minoxidil | Tadalafil may increase the antihypertensive activities of Minoxidil. |
| Mitotane | The serum concentration of Tadalafil can be decreased when it is combined with Mitotane. |
| Moexipril | Tadalafil may increase the antihypertensive activities of Moexipril. |
| Molsidomine | Molsidomine may increase the hypotensive activities of Tadalafil. |
| Moxonidine | Tadalafil may increase the antihypertensive activities of Moxonidine. |
| Nadolol | Tadalafil may increase the antihypertensive activities of Nadolol. |
| Nebivolol | Tadalafil may increase the antihypertensive activities of Nebivolol. |
| Nefazodone | The serum concentration of Tadalafil can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Tadalafil can be increased when it is combined with Nelfinavir. |
| Netupitant | The serum concentration of Tadalafil can be increased when it is combined with Netupitant. |
| Nicardipine | Tadalafil may increase the antihypertensive activities of Nicardipine. |
| Nifedipine | Tadalafil may increase the antihypertensive activities of Nifedipine. |
| Nimodipine | Tadalafil may increase the antihypertensive activities of Nimodipine. |
| Nisoldipine | Tadalafil may increase the antihypertensive activities of Nisoldipine. |
| Nitroglycerin | Tadalafil may increase the vasodilatory activities of Nitroglycerin. |
| Nitroprusside | Tadalafil may increase the antihypertensive activities of Nitroprusside. |
| Olmesartan | Tadalafil may increase the antihypertensive activities of Olmesartan. |
| Palbociclib | The serum concentration of Tadalafil can be increased when it is combined with Palbociclib. |
| Penbutolol | Tadalafil may increase the antihypertensive activities of Penbutolol. |
| Perindopril | Tadalafil may increase the antihypertensive activities of Perindopril. |
| Phenobarbital | The serum concentration of Tadalafil can be decreased when it is combined with Phenobarbital. |
| Phenoxybenzamine | Tadalafil may increase the hypotensive activities of Phenoxybenzamine. |
| Phentolamine | Tadalafil may increase the hypotensive activities of Phentolamine. |
| Phenytoin | The serum concentration of Tadalafil can be decreased when it is combined with Phenytoin. |
| Pindolol | Tadalafil may increase the antihypertensive activities of Pindolol. |
| Posaconazole | The serum concentration of Tadalafil can be increased when it is combined with Posaconazole. |
| Prazosin | Tadalafil may increase the hypotensive activities of Prazosin. |
| Primidone | The serum concentration of Tadalafil can be decreased when it is combined with Primidone. |
| Propranolol | Tadalafil may increase the antihypertensive activities of Propranolol. |
| Quinapril | Tadalafil may increase the antihypertensive activities of Quinapril. |
| Ramipril | Tadalafil may increase the antihypertensive activities of Ramipril. |
| Reserpine | Tadalafil may increase the antihypertensive activities of Reserpine. |
| Rifabutin | The serum concentration of Tadalafil can be decreased when it is combined with Rifabutin. |
| Rifampicin | The serum concentration of Tadalafil can be decreased when it is combined with Rifampicin. |
| Rifapentine | The serum concentration of Tadalafil can be decreased when it is combined with Rifapentine. |
| Riociguat | Tadalafil may increase the hypotensive activities of Riociguat. |
| Ritonavir | The serum concentration of Tadalafil can be increased when it is combined with Ritonavir. |
| Saquinavir | The serum concentration of Tadalafil can be increased when it is combined with Saquinavir. |
| Sildenafil | The risk or severity of adverse effects can be increased when Tadalafil is combined with Sildenafil. |
| Silodosin | Tadalafil may increase the hypotensive activities of Silodosin. |
| Simeprevir | The serum concentration of Tadalafil can be increased when it is combined with Simeprevir. |
| Sotalol | Tadalafil may increase the antihypertensive activities of Sotalol. |
| Spironolactone | Tadalafil may increase the antihypertensive activities of Spironolactone. |
| Stiripentol | The serum concentration of Tadalafil can be increased when it is combined with Stiripentol. |
| Tamsulosin | Tadalafil may increase the hypotensive activities of Tamsulosin. |
| Telaprevir | The serum concentration of Tadalafil can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Tadalafil can be increased when it is combined with Telithromycin. |
| Telmisartan | Tadalafil may increase the antihypertensive activities of Telmisartan. |
| Terazosin | Tadalafil may increase the hypotensive activities of Terazosin. |
| Tetrahydrobiopterin | Tetrahydrobiopterin may increase the hypotensive activities of Tadalafil. |
| Timolol | Tadalafil may increase the antihypertensive activities of Timolol. |
| Tipranavir | The serum concentration of Tadalafil can be increased when it is combined with Tipranavir. |
| Torasemide | Tadalafil may increase the antihypertensive activities of Torasemide. |
| Trandolapril | Tadalafil may increase the antihypertensive activities of Trandolapril. |
| Triamterene | Tadalafil may increase the antihypertensive activities of Triamterene. |
| Valsartan | Tadalafil may increase the antihypertensive activities of Valsartan. |
| Vardenafil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Tadalafil. |
| Verapamil | Tadalafil may increase the antihypertensive activities of Verapamil. |
| Voriconazole | The serum concentration of Tadalafil can be increased when it is combined with Voriconazole. |
| Drug | Interaction |
|---|---|
| Acebutolol | Tadalafil may increase the antihypertensive activities of Acebutolol. |
| Alfuzosin | Tadalafil may increase the hypotensive activities of Alfuzosin. |
| Aliskiren | Tadalafil may increase the antihypertensive activities of Aliskiren. |
| Alprostadil | The risk or severity of adverse effects can be increased when Tadalafil is combined with Alprostadil. |
| Amiloride | Tadalafil may increase the antihypertensive activities of Amiloride. |
| Amlodipine | Tadalafil may increase the antihypertensive activities of Amlodipine. |
| Amyl Nitrite | Tadalafil may increase the vasodilatory activities of Amyl Nitrite. |
| Aprepitant | The serum concentration of Tadalafil can be increased when it is combined with Aprepitant. |
| Atazanavir | The serum concentration of Tadalafil can be increased when it is combined with Atazanavir. |
| Atenolol | Tadalafil may increase the antihypertensive activities of Atenolol. |
| Avanafil | The risk or severity of adverse effects can be increased when Tadalafil is combined with Avanafil. |
| Azilsartan medoxomil | Tadalafil may increase the antihypertensive activities of Azilsartan medoxomil. |
| Benazepril | Tadalafil may increase the antihypertensive activities of Benazepril. |
| Bendroflumethiazide | Tadalafil may increase the antihypertensive activities of Bendroflumethiazide. |
| Betaxolol | Tadalafil may increase the antihypertensive activities of Betaxolol. |
| Bisoprolol | Tadalafil may increase the antihypertensive activities of Bisoprolol. |
| Boceprevir | The serum concentration of Tadalafil can be increased when it is combined with Boceprevir. |
| Bosentan | The serum concentration of Tadalafil can be decreased when it is combined with Bosentan. |
| Bumetanide | Tadalafil may increase the antihypertensive activities of Bumetanide. |
| Candesartan | Tadalafil may increase the antihypertensive activities of Candesartan. |
| Captopril | Tadalafil may increase the antihypertensive activities of Captopril. |
| Carbamazepine | The serum concentration of Tadalafil can be decreased when it is combined with Carbamazepine. |
| Carvedilol | Tadalafil may increase the antihypertensive activities of Carvedilol. |
| Ceritinib | The serum concentration of Tadalafil can be increased when it is combined with Ceritinib. |
| Chlorothiazide | Tadalafil may increase the antihypertensive activities of Chlorothiazide. |
| Chlorthalidone | Tadalafil may increase the antihypertensive activities of Chlorthalidone. |
| Cilazapril | Tadalafil may increase the antihypertensive activities of Cilazapril. |
| Clarithromycin | The serum concentration of Tadalafil can be increased when it is combined with Clarithromycin. |
| Clevidipine | Tadalafil may increase the antihypertensive activities of Clevidipine. |
| Clonidine | Tadalafil may increase the antihypertensive activities of Clonidine. |
| Cobicistat | The serum concentration of Tadalafil can be increased when it is combined with Cobicistat. |
| Conivaptan | The serum concentration of Tadalafil can be increased when it is combined with Conivaptan. |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Tadalafil. |
| Darunavir | The serum concentration of Tadalafil can be increased when it is combined with Darunavir. |
| Dasatinib | The serum concentration of Tadalafil can be increased when it is combined with Dasatinib. |
| Diltiazem | Tadalafil may increase the antihypertensive activities of Diltiazem. |
| Doxazosin | Tadalafil may increase the hypotensive activities of Doxazosin. |
| Enalapril | Tadalafil may increase the antihypertensive activities of Enalapril. |
| Enalaprilat | Tadalafil may increase the antihypertensive activities of Enalaprilat. |
| Enzalutamide | The serum concentration of Tadalafil can be decreased when it is combined with Enzalutamide. |
| Eplerenone | Tadalafil may increase the antihypertensive activities of Eplerenone. |
| Eprosartan | Tadalafil may increase the antihypertensive activities of Eprosartan. |
| Erythrityl Tetranitrate | Tadalafil may increase the vasodilatory activities of Erythrityl Tetranitrate. |
| Esmolol | Tadalafil may increase the antihypertensive activities of Esmolol. |
| Ethacrynic acid | Tadalafil may increase the antihypertensive activities of Ethacrynic acid. |
| Ethanol | Ethanol may increase the hypotensive activities of Tadalafil. |
| Etravirine | The serum concentration of Tadalafil can be decreased when it is combined with Etravirine. |
| Felodipine | Tadalafil may increase the antihypertensive activities of Felodipine. |
| Fluconazole | The serum concentration of Tadalafil can be increased when it is combined with Fluconazole. |
| Fosaprepitant | The serum concentration of Tadalafil can be increased when it is combined with Fosaprepitant. |
| Fosinopril | Tadalafil may increase the antihypertensive activities of Fosinopril. |
| Fosphenytoin | The serum concentration of Tadalafil can be decreased when it is combined with Fosphenytoin. |
| Furosemide | Tadalafil may increase the antihypertensive activities of Furosemide. |
| Fusidic Acid | The serum concentration of Tadalafil can be increased when it is combined with Fusidic Acid. |
| Guanfacine | Tadalafil may increase the antihypertensive activities of Guanfacine. |
| Hydralazine | Tadalafil may increase the antihypertensive activities of Hydralazine. |
| Hydrochlorothiazide | Tadalafil may increase the antihypertensive activities of Hydrochlorothiazide. |
| Idelalisib | The serum concentration of Tadalafil can be increased when it is combined with Idelalisib. |
| Indapamide | Tadalafil may increase the antihypertensive activities of Indapamide. |
| Indinavir | The serum concentration of Tadalafil can be increased when it is combined with Indinavir. |
| Irbesartan | Tadalafil may increase the antihypertensive activities of Irbesartan. |
| Isosorbide | Tadalafil may increase the vasodilatory activities of Isosorbide. |
| Isosorbide Dinitrate | Tadalafil may increase the vasodilatory activities of Isosorbide Dinitrate. |
| Isosorbide Mononitrate | Tadalafil may increase the vasodilatory activities of Isosorbide Mononitrate. |
| Isradipine | Tadalafil may increase the antihypertensive activities of Isradipine. |
| Itraconazole | The serum concentration of Tadalafil can be increased when it is combined with Itraconazole. |
| Ivacaftor | The serum concentration of Tadalafil can be increased when it is combined with Ivacaftor. |
| Ketoconazole | The serum concentration of Tadalafil can be increased when it is combined with Ketoconazole. |
| Labetalol | Tadalafil may increase the antihypertensive activities of Labetalol. |
| Lisinopril | Tadalafil may increase the antihypertensive activities of Lisinopril. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Tadalafil. |
| Losartan | Tadalafil may increase the antihypertensive activities of Losartan. |
| Luliconazole | The serum concentration of Tadalafil can be increased when it is combined with Luliconazole. |
| Mannitol | Tadalafil may increase the antihypertensive activities of Mannitol. |
| Mecamylamine | Tadalafil may increase the antihypertensive activities of Mecamylamine. |
| Methyclothiazide | Tadalafil may increase the antihypertensive activities of Methyclothiazide. |
| Methyldopa | Tadalafil may increase the antihypertensive activities of Methyldopa. |
| Metolazone | Tadalafil may increase the antihypertensive activities of Metolazone. |
| Metoprolol | Tadalafil may increase the antihypertensive activities of Metoprolol. |
| Mifepristone | The serum concentration of Tadalafil can be increased when it is combined with Mifepristone. |
| Minoxidil | Tadalafil may increase the antihypertensive activities of Minoxidil. |
| Mitotane | The serum concentration of Tadalafil can be decreased when it is combined with Mitotane. |
| Moexipril | Tadalafil may increase the antihypertensive activities of Moexipril. |
| Molsidomine | Molsidomine may increase the hypotensive activities of Tadalafil. |
| Moxonidine | Tadalafil may increase the antihypertensive activities of Moxonidine. |
| Nadolol | Tadalafil may increase the antihypertensive activities of Nadolol. |
| Nebivolol | Tadalafil may increase the antihypertensive activities of Nebivolol. |
| Nefazodone | The serum concentration of Tadalafil can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Tadalafil can be increased when it is combined with Nelfinavir. |
| Netupitant | The serum concentration of Tadalafil can be increased when it is combined with Netupitant. |
| Nicardipine | Tadalafil may increase the antihypertensive activities of Nicardipine. |
| Nifedipine | Tadalafil may increase the antihypertensive activities of Nifedipine. |
| Nimodipine | Tadalafil may increase the antihypertensive activities of Nimodipine. |
| Nisoldipine | Tadalafil may increase the antihypertensive activities of Nisoldipine. |
| Nitroglycerin | Tadalafil may increase the vasodilatory activities of Nitroglycerin. |
| Nitroprusside | Tadalafil may increase the antihypertensive activities of Nitroprusside. |
| Olmesartan | Tadalafil may increase the antihypertensive activities of Olmesartan. |
| Palbociclib | The serum concentration of Tadalafil can be increased when it is combined with Palbociclib. |
| Penbutolol | Tadalafil may increase the antihypertensive activities of Penbutolol. |
| Perindopril | Tadalafil may increase the antihypertensive activities of Perindopril. |
| Phenobarbital | The serum concentration of Tadalafil can be decreased when it is combined with Phenobarbital. |
| Phenoxybenzamine | Tadalafil may increase the hypotensive activities of Phenoxybenzamine. |
| Phentolamine | Tadalafil may increase the hypotensive activities of Phentolamine. |
| Phenytoin | The serum concentration of Tadalafil can be decreased when it is combined with Phenytoin. |
| Pindolol | Tadalafil may increase the antihypertensive activities of Pindolol. |
| Posaconazole | The serum concentration of Tadalafil can be increased when it is combined with Posaconazole. |
| Prazosin | Tadalafil may increase the hypotensive activities of Prazosin. |
| Primidone | The serum concentration of Tadalafil can be decreased when it is combined with Primidone. |
| Propranolol | Tadalafil may increase the antihypertensive activities of Propranolol. |
| Quinapril | Tadalafil may increase the antihypertensive activities of Quinapril. |
| Ramipril | Tadalafil may increase the antihypertensive activities of Ramipril. |
| Reserpine | Tadalafil may increase the antihypertensive activities of Reserpine. |
| Rifabutin | The serum concentration of Tadalafil can be decreased when it is combined with Rifabutin. |
| Rifampicin | The serum concentration of Tadalafil can be decreased when it is combined with Rifampicin. |
| Rifapentine | The serum concentration of Tadalafil can be decreased when it is combined with Rifapentine. |
| Riociguat | Tadalafil may increase the hypotensive activities of Riociguat. |
| Ritonavir | The serum concentration of Tadalafil can be increased when it is combined with Ritonavir. |
| Saquinavir | The serum concentration of Tadalafil can be increased when it is combined with Saquinavir. |
| Sildenafil | The risk or severity of adverse effects can be increased when Tadalafil is combined with Sildenafil. |
| Silodosin | Tadalafil may increase the hypotensive activities of Silodosin. |
| Simeprevir | The serum concentration of Tadalafil can be increased when it is combined with Simeprevir. |
| Sotalol | Tadalafil may increase the antihypertensive activities of Sotalol. |
| Spironolactone | Tadalafil may increase the antihypertensive activities of Spironolactone. |
| Stiripentol | The serum concentration of Tadalafil can be increased when it is combined with Stiripentol. |
| Tamsulosin | Tadalafil may increase the hypotensive activities of Tamsulosin. |
| Telaprevir | The serum concentration of Tadalafil can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Tadalafil can be increased when it is combined with Telithromycin. |
| Telmisartan | Tadalafil may increase the antihypertensive activities of Telmisartan. |
| Terazosin | Tadalafil may increase the hypotensive activities of Terazosin. |
| Tetrahydrobiopterin | Tetrahydrobiopterin may increase the hypotensive activities of Tadalafil. |
| Timolol | Tadalafil may increase the antihypertensive activities of Timolol. |
| Tipranavir | The serum concentration of Tadalafil can be increased when it is combined with Tipranavir. |
| Torasemide | Tadalafil may increase the antihypertensive activities of Torasemide. |
| Trandolapril | Tadalafil may increase the antihypertensive activities of Trandolapril. |
| Triamterene | Tadalafil may increase the antihypertensive activities of Triamterene. |
| Valsartan | Tadalafil may increase the antihypertensive activities of Valsartan. |
| Vardenafil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Tadalafil. |
| Verapamil | Tadalafil may increase the antihypertensive activities of Verapamil. |
| Voriconazole | The serum concentration of Tadalafil can be increased when it is combined with Voriconazole. |
Food Interactions:
- Not Available
Taxonomy
Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- 2,5-dioxopiperazines
- Acetals
- Azacyclic compounds
- Benzenoids
- Benzodioxoles
- Carbonyl compounds
- Heteroaromatic compounds
- Hydrocarbon derivatives
- Indoles
- Lactams
- N-methylpiperazines
- Oxacyclic compounds
- Pyrroles
- Tertiary amines
- Tertiary carboxylic acid amides
substituent:
- 1,4-diazinane
- 2,5-dioxopiperazine
- Acetal
- Amine
- Aromatic heteropolycyclic compound
- Azacycle
- Benzenoid
- Benzodioxole
- Beta-carboline
- Carbonyl group
- Carboxamide group
- Carboxylic acid derivative
- Dioxopiperazine
- Heteroaromatic compound
- Hydrocarbon derivative
- Indole
- Lactam
- N-alkylpiperazine
- N-methylpiperazine
- Organonitrogen compound
- Organooxygen compound
- Oxacycle
- Piperazine
- Pyrrole
- Tertiary amine
- Tertiary carboxylic acid amide
References
Synthesis Reference: Ben-Zion Dolitzky, Dov Diller, "Preparation of tadalafil intermediates." U.S. Patent US20060276652, issued December 07, 2006.
General Reference: # Naeije R, Huez S: Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother. 2007 Oct;8(14):2247-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17927481 # Burnett AL: Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health. J Androl. 2007 Oct 17;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17942972 # Guazzi M, Samaja M: The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem. 2007;14(20):2181-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17691956
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # Naeije R, Huez S: Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother. 2007 Oct;8(14):2247-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17927481 # Burnett AL: Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health. J Androl. 2007 Oct 17;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17942972 # Guazzi M, Samaja M: The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem. 2007;14(20):2181-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17691956
External Links:
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic3/cialis.htm |
| PDRhealth | http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cia1687.shtml |
| Drugs.com | http://www.drugs.com/tadalafil.html |
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic3/cialis.htm |
| PDRhealth | http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cia1687.shtml |
| Drugs.com | http://www.drugs.com/tadalafil.html |
ATC Codes:
- Array
AHFS Codes:
- 24:12.12
MSDS: Download